# RemeGen Co., Ltd. clinical trials: 83 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 83 trials with RemeGen Co., Ltd. as lead sponsor, 29 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by RemeGen Co., Ltd.: 83 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/remegen-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 83
- Recruiting or not yet: 29
- Read on: November 19, 2026

## Trials

The 25 newest of 83, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07936487 | IIIb Trial for RC28-E Injection in Participants With DME and wAMD | RemeGen Co., Ltd. | Phase 3 | Not yet recruiting | Diabetic Macular Edema (DME), wAMD | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936487) |
| November 13, 2026 | NCT07935369 | RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma | RemeGen Co., Ltd. | Phase 2/3 | Not yet recruiting | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | 680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935369) |
| October 26, 2026 | NCT07895355 | Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable... | RemeGen Co., Ltd. | Phase 2 | Not yet recruiting | Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy | 412 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895355) |
| October 14, 2026 | NCT07874282 | Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With... | RemeGen Co., Ltd. | Phase 2 | Not yet recruiting | Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874282) |
| September 21, 2026 | NCT07829549 | Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell... | RemeGen Co., Ltd. | Phase 3 | Recruiting | Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829549) |
| April 17, 2026 | NCT07537881 | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors | RemeGen Co., Ltd. | Phase 1/2 | Recruiting | Solid Tumors | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07537881) |
| March 27, 2026 | NCT07495033 | Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung... | RemeGen Co., Ltd. | Phase 3 | Not yet recruiting | CTD-ILD | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07495033) |
| March 10, 2026 | NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | RemeGen Co., Ltd. | Phase 2/3 | Recruiting | Colorectal (Colon or Rectal) Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462143) |
| February 18, 2026 | NCT07416474 | RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer... | RemeGen Co., Ltd. | Phase 3 | Recruiting | Non-Small Cell Lung Cancer | 574 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416474) |
| January 2, 2026 | NCT07315750 | A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without... | RemeGen Co., Ltd. | Phase 3 | Recruiting | Gastric Carcinoma | 555 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07315750) |
| November 25, 2025 | NCT07249632 | A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | RemeGen Co., Ltd. | Phase 3 | Recruiting | Myasthenia Gravis, Ocular | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249632) |
| August 5, 2025 | NCT07105215 | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors | RemeGen Co., Ltd. | Phase 1/2 | Recruiting | Solid Tumors | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105215) |
| May 8, 2025 | NCT06962865 | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable... | RemeGen Co., Ltd. | Phase 2 | Recruiting | Non-Small Cell Lung Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06962865) |
| April 25, 2025 | NCT06944496 | A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low... | RemeGen Co., Ltd. | Phase 3 | Not yet recruiting | Gastric Carcinoma | 616 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06944496) |
| March 19, 2025 | NCT06883630 | A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC | RemeGen Co., Ltd. | Phase 1 | Active not recruiting | Non-Small Cell Lung Cancer | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06883630) |
| October 15, 2024 | NCT06642545 | Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer | RemeGen Co., Ltd. | Phase 2 | Recruiting | Breast Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06642545) |
| August 12, 2024 | NCT06549959 | A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in... | RemeGen Co., Ltd. | Phase 1 | Unknown | Healthy | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06549959) |
| April 29, 2024 | NCT06389006 | To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in... | RemeGen Co., Ltd. | Phase 2 | Recruiting | Breast Cancer | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06389006) |
| April 22, 2024 | NCT06378242 | To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk... | RemeGen Co., Ltd. | Phase 1/2 | Recruiting | High-risk Non-muscle Invasive Bladder Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06378242) |
| January 26, 2024 | NCT06227156 | Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer | RemeGen Co., Ltd. | Phase 2 | Unknown | Castration-resistant Prostate Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06227156) |
| January 26, 2024 | NCT06227117 | Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer | RemeGen Co., Ltd. | Phase 2 | Recruiting | Breast Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06227117) |
| January 24, 2024 | NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression... | RemeGen Co., Ltd. | Phase 2/3 | Recruiting | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06221748) |
| December 20, 2023 | NCT06178159 | DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer | RemeGen Co., Ltd. | Phase 2 | Recruiting | Breast Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06178159) |
| December 15, 2023 | NCT06173037 | RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | RemeGen Co., Ltd. | Phase 2 | Completed | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06173037) |
| December 4, 2023 | NCT06155396 | A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With... | RemeGen Co., Ltd. | Phase 2 | Recruiting | Cervical Cancer | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06155396) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 14 |
| Phase 2 | 32 |
| Phase 2/3 | 5 |
| Phase 3 | 18 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Recruiting | 22 |
| Unknown | 18 |
| Not yet recruiting | 7 |
| Terminated | 4 |
| Active not recruiting | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Stomach Neoplasms | 8 |
| Breast Neoplasms | 7 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Carcinoma, Transitional Cell | 5 |
| Lupus Erythematosus, Systemic | 4 |
| Autoimmune Diseases | 3 |
| Glomerulonephritis, IGA | 3 |
| Melanoma | 2 |
| Lymphoma, Follicular | 2 |
| Arthritis, Rheumatoid | 2 |
| Myasthenia Gravis | 2 |
| Connective Tissue Diseases | 1 |
| Non-Muscle Invasive Bladder Neoplasms | 1 |
| Muscle Weakness | 1 |
| Gastrointestinal Neoplasms | 1 |
| Breast Diseases | 1 |
| Colonic Neoplasms | 1 |
| Biliary Tract Neoplasms | 1 |
| Lupus Nephritis | 1 |
| Nephritis | 1 |
| Diabetic Retinopathy | 1 |
| Neuromyelitis Optica | 1 |
| Carcinoma, Renal Cell | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Colorectal Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Woodworking supply stores in the United States](https://specstream.ai/data/businesses/woodworking-supply-stores/united-states)
- [Sand and gravel suppliers in the United States](https://specstream.ai/data/businesses/sand-and-gravel-suppliers/united-states)
- [Middle schools in the United States](https://specstream.ai/data/businesses/middle-schools/united-states)
- [Glass companies in the United States](https://specstream.ai/data/businesses/glass-companies/united-states)
- [Concierge medicine practices in the United States](https://specstream.ai/data/businesses/concierge-medicine-practices/united-states)
- [Artificial turf companies in the United States](https://specstream.ai/data/businesses/artificial-turf-companies/united-states)
